Search

Sujan D Shresta

from San Diego, CA
Age ~53
Get Report
Related to:
Erik Hawkes Andersen, 51Ericka G Gowans, 48
Connected to:
Aakash Shrestha, 34Ambika Shrestha, 58Ashis Shrestha, 40Ashwin K Shrestha, 31Aubrey A Shrestha, 38Bipul Shrestha, 43Bishwash Shrestha, 33Christina Shrestha, 36Deepesh Shrestha, 44Dipendra B Shrestha, 51

Sujan Shresta Phones & Addresses

  • 6820 Condon Dr, San Diego, CA 92122 (858) 587-3694
  • Berkeley, CA
  • Fremont, CA
  • Morgan Hill, CA
  • Saint Louis, MO
  • 6820 Condon Dr, San Diego, CA 92122

Work

Company: La jolla institute for allergy and immunology Apr 1, 2011 Position: Associate professor

Education

Degree: Bachelors, Bachelor of Arts School / High School: Smith College

Skills

Flow Cytometry • Immunology • Molecular Biology • Animal Models • Cell Biology

Industries

Research

Resumes

Resumes

Sujan Shresta Photo 1

Associate Professor

View page
Location:
San Diego, CA
Industry:
Research
Work:
La Jolla Institute For Allergy and Immunology
Associate Professor
Education:
Smith College
Bachelors, Bachelor of Arts Washington University In St. Louis
Doctorates, Doctor of Philosophy, Philosophy, Immunology
Skills:
Flow Cytometry
Immunology
Molecular Biology
Animal Models
Cell Biology

Publications

Us Patents

Compositions And Methods For Dengue Virus (Dv) Treatment And Vaccination

View page
US Patent:
20110150914, Jun 23, 2011
Filed:
Jun 9, 2009
Appl. No.:
12/996612
Inventors:
Sujan Shresta - San Diego CA, US
Laurene E. Yauch - La Jolla CA, US
Alessandro Sette - La Jolla CA, US
Assignee:
LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY - La Jolla CA
International Classification:
A61K 39/12
A61K 47/00
C12N 5/00
C07K 7/06
C07K 7/08
C07K 14/005
C07H 21/04
A61P 31/12
US Classification:
4241861, 4242041, 4242781, 435325, 530324, 530325, 530326, 530327, 530328, 530329, 530330, 530350, 536 2372
Abstract:
The invention relates to Dengue virus (DV) peptides and compositions thereof, and methods that employ Dengue virus (DV) peptides and compositions thereof. The invention includes among other things, methods of treating Dengue virus (DV) infection or pathology, which include, for example, administering Dengue virus (DV) peptide T cell epitope, to treat a Dengue virus (DV) infection or pathology. The invention includes among other things Dengue virus (DV) vaccination and immunization methods.

Flavivirus Peptide Sequences, Epitopes, And Methods And Uses Thereof

View page
US Patent:
20200237892, Jul 30, 2020
Filed:
Aug 9, 2019
Appl. No.:
16/537447
Inventors:
- La Jolla CA, US
Sujan Shresta - La Jolla CA, US
International Classification:
A61K 39/12
C07K 7/06
G01N 33/68
G01N 33/50
Abstract:
The present application relates to composition of matter, processes and use of composition of matter relating to flavivirus peptides and epitopes, for example, for therapeutic or preventative vaccination against a flavivirus, and/or for inducing, enhancing, or sustaining an immune response against a flavivirus, and/or for detecting an infection with or an exposure to a flavivirus in a subject. The flavivirus may be for example the Zika and/or Dengue virus.

Protection Against Dengue Virus And Prevention Of Severe Dengue Disease

View page
US Patent:
20150150960, Jun 4, 2015
Filed:
Jun 25, 2012
Appl. No.:
14/128268
Inventors:
Sujan Shresta - San Diego CA, US
Assignee:
LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY - San Diego CA
International Classification:
A61K 39/12
C12N 7/00
Abstract:
The invention provides uses, methods and compositions for eliciting, stimulating, inducing, promoting, increasing, or enhancing an anti-Dengue virus T cell response in a subject.
Control profile
Sujan D Shresta from San Diego, CA, age ~53 Get Report